Clinical Trial

PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study

Study acronym: P-CCROSS

Recruiting Phase 4

Summary

P-CCROSS is a randomized, prospective monocentric phase 4 study with a crossover study design. The aim of the study is to compare patient satisfaction (by means of questionnaires) and treatment compliance with IVF treatment with CFA (corifollitropin alfa) and PPOS (Progestin-Primed Ovarian Stimulation) versus conventional IVF treatment with a recombinant FSH/GnRH antagonist. The study will also compare patients undergoing elective fertility preservation versus PGT-A (pre-implantation genetic testing for aneuploidy) patients.The study will have a crossover design so that patients will receive both forms of treatment. The investigators will also compare the endocrine profile and ovarian response of CFA/PPOS versus rFSH/GnRH ovarian stimulation cycles.

Protocol Amendment History 7 amendments

This ClinicalTrials.gov record has been amended 7 times since 2023-12-08; most recent amendment 2025-12-18.

Status change: Not Yet Recruiting → Recruiting 2025-12-11

Trial Details

NCT Number	NCT06175832
Lead Sponsor	University Hospital, Ghent Collaborators: Organon
Conditions	Ovarian Stimulation, Quality of Life, Preimplantation Genetic Testing, Fertility Preservation
Enrollment	60 participants
Start Date	2025-01-27
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-12-26